Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi- nations of DAAs can cure infection with HCV in 12 weeks, are highly effective <span class="attribute-to-highlight medbox">and</span> have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim- ited. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- <span class="attribute-to-highlight medbox">and</span> low- income countries alike. Now there is <span class="attribute-to-highlight medbox">a</span> divide between those countries where, because of intellectual property barriers, prices have remained (very) high <span class="attribute-to-highlight medbox">and</span> other countries where generics are, or can be, available at much lower prices. The result is <span class="attribute-to-highlight medbox">a</span> dual market